secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tenaya Therapeutics, Inc. (TNYA)
CIK:        0001858848
Form:       8-K
Filed at:   2024-12-17T23:59:59+00:00
Accession:  0001193125-24-280112
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tenaya's TN-201 shows robust cardiac transduction, increasing mRNA and protein in 3 HCM patients
--------------------------------------------------------------------------------

- TN-201 well tolerated at 3E13 vg/kg; no cardiac toxicities or TMA; liver enzyme elevations managed with corticosteroids.
- Robust cardiac transduction at Week 8 above preclinical efficacy levels; TN-201 mRNA increased 50% at Week 52 in Patient 1.
- MyBP-C protein level increased 3% from Week 8 to 52 in Patient 1; baseline biopsies added for future quantification.
- Clinical measures mostly stable/improved: NT-proBNP stable, troponin I normalized in Patient 2; NYHA class improved.
- Further data from Cohort 1 and higher-dose Cohort 2 expected in 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1858848/000119312524280112/0001193125-24-280112-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1858848/000119312524280112/d883027d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-280112

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer